Increased levels of tissue inhibitor of metalloproteinase-1 in human hepatocellular carcinoma

Liver International

Volumn 24, Issue 4, 2004, Pages 379-383

  Matsumoto, Elji ^a   Nakatsukasa, Harushige ^a   Nouso, Kazuhiro ^a   Kobayashi, Yoshiyuki ^a   Nakamura, Shinichiro ^a   Suzuki, Mayumi ^a   Takuma, Yoshitaka ^a   Tanaka, Hironori ^a   Fujikawa, Tatsuya ^a   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Differentiation grade; Hepatocellular carcinoma; Prognosis; Tissue inhibitor of metalloproteinases (TIMPs)

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; REGULATORY MECHANISM; SUPERNATANT; TISSUE HOMOGENATE; TUMOR DIFFERENTIATION;

EID: 4444320917     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.0923.x     Document Type: Article

References (24)

1. Schafer D F, Sorrell M F. Hepatocellular carcinoma. Lancet 1999; 353: 1253-7.
2. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
3. Koike Y, Shiratori Y, Sato S, et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000; 32: 1216-23.
4. Ko S, Kanehiro H, Hisanaga M, Nagao M, Ikeda N, Nakajima Y. Liver fibrosis increases the risk of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Br J Surg 2002; 89: 57-62.
5. Ng I O, Lai E C, Ng M M, Fan S T. Tumor encapsulation in hepatocellular carcinoma. A pathologic study of 189 cases. Cancer 1992; 70: 45-9.
6. Torimura T, Ueno T, Inuzuka S, Tanaka M, Abe H, Tanikawa K. Mechanism of fibrous capsule formation surrounding hepatocellular carcinoma. Immunohistochemical study. Arch Pathol Lab Med 1991; 115: 365-71.
7. Liotta L A, Steeg P S, Stetler-Stevenson W G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
8. Stetler-Stevenson W G, Aznavoorian S, Liotta L A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541-73.
9. Chieh C, Zena W. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11: 37-43.
10. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-83.
11. Umenishi F, Umeda M, Miyazaki K. Efficient purification of TIMP-2 from culture medium conditioned by human hepatoma cell line, and its inhibitory effects on metalloproteinases and in vitro tumor invasion. J Biochem (Tokyo) 1991; 110: 189-95.
12. Nakatsukasa H, Ashida K, Higashi T, et al. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas. Hepatology 1996; 24: 82-8.
13. Ashida K, Nakatsukasa H, Higashi T, et al. Cellular distribution of 92-kd type IV collagenase/gelatinase B in human hepatocellular carcinoma. Am J Pathol 1996; 149: 1803-11.
14. Woessner J F Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-54.
15. Giannella G, Bergamini C, Marinosci F, et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002; 97: 425-31.
16. Ylisirnio S, Hoyhtya M, Makitaro R, et al. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001; 7: 1633-7.
17. Yoshikawa T, Tsuburaya A, Kobayashi O, et al. Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma a new biomarker for invasion and its impact on survival. Cancer 2001; 911: 1739-44.
18. Nuovo G J, MacConnell P B, Simsir A, Valea F, French D L. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995; 55: 267-75.
19. Kodama S, Iwata K, Iwta H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma. J Immunol Methods 1990; 127: 103-8.
20. Liver Cancer Study Group of Japan Primary liver cancer in Japan: clinicopathologic features and results of surgical treatment. Ann Surg 1990; 2: 277-87.
21. Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996; 11: 720-6.
22. Murawaki Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 1997; 26: 1213-9.
23. Walsh K M, Timms P, Campbell S, MacSween R N, Morris A J. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999; 44: 624-30.
24. Murawaki Y, Yamamoto H, Kawasaki H, Shima H. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma. Clin Chim Acta 1993; 218: 47-58.